PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM AB SCIENCE SECURES EUR 25 MILLION CLINICAL TRIAL INSURANCE FOR ITS PHASE III TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS THE POLICY ...

Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology, ...

Funding will enable progress on the ADCE-T02 Phase I Tiffany-01 cohort expansion in a range of solid tumours.

In connection with the collaboration, Mayo Clinic will make an equity investment in Sana Biotechnology, reflecting a shared commitment to advancing innovative approaches aimed at improving care for ...

Over the past several years, pharmaceutical companies have been steadily integrating artificial intelligence (AI) into many aspects of clinical development. Today, AI’s impact is being felt from the ...

Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard’s lead asset AT-108 into Phase 1 ...

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, outlines future steps for the clinical development of rilzabrutinib, as well as promising data to advance to phase 3 studies ...

Dr. Daniels is a seasoned biotechnology executive with more than two decades of experience spanning clinical development, regulatory strategy, corporate operations, and business development. He most ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Science Exchange, the leading SaaS provider of supplier orchestration solutions for the life sciences industry, today announced the launch of its Clinical ...

The OpenAI partnership is a credible productivity catalyst across discovery, manufacturing, and commercial ops, directly ...

The non-small cell lung cancer clinical trial analysis report delivers important insights into ongoing research of 120+ ...